Name of this trial: TROPION-Urothelial03
What type of cancer is this for? Urothelial Carcinoma
Who is this trial for? Subjects With Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)
What biomarkers are involved? TROP2 Protein Expression
What is the National Clinical Trial #? NCT07129993; https://clinicaltrials.gov/study/NCT07129993
Brief summary of this trial: A Randomized, Open-Label, Phase 2/3 Study of Datopotamab Deruxtecan (Dato-DXd) plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Participants with Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) who Progressed During or After Enfortumab Vedotin (EV) plus Pembrolizumab Combination Treatment
Need to know: Must have confirmed unresectable locally advanced (T4b, any N; or any T, N 2-3) or metastatic (any T, any N, M1) urothelial carcinoma of the bladder, renal pelvis, ureter, or urethra. No prior systemic treatment other than the combination of EV and pembrolizumab.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email [email protected]
Name of this trial: RC48 G001 (SEAGEN)
What type of cancer is this for? Locally advanced or metastatic Urothelial Carcinoma
Who is this trial for? Patients locally advanced, unresectable, or metastatic urothelial carcinoma, including urothelial originating from the renal pelvis, ureters, bladder, or urethra.
What biomarkers are involved? HER2 positive which will be centrally confirmed.
What is the National Clinical Trial #? NCT04879329
Brief summary of this trial: Trial is evaluating safety and efficacy of Disitamab Vedotin alone or in combination with Pembrolizumab. Patients who have had 1 or 2 previous lines of treatment will receive study drug every 2 weeks. Patients who have not been treated for locally advanced or metastatic disease will receive either study drug every 2 weeks with Pembrolizumab every 6 weeks, or study drug only every 2 weeks.
Need to know: Patients can have received 0, 1, or 2 lines of previous systemic therapy for locally or metastatic disease and progressed. Patients must have received an anti-PD-1 therapy.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email [email protected]